C&R Research Inc. (KOSDAQ:359090)

South Korea · Delayed Price · Currency is KRW

2,280.00

-15.00 (-0.65%)

At close: Oct 2, 2026

Market Cap	26.20B -53.5%
Revenue (ttm)	63.55B -1.7%
Net Income	1.66B -56.7%
EPS	143.88 -57.4%
Shares Out	11.49M
PE Ratio	15.85
Forward PE	n/a
Dividend	50.00 (2.19%)
Ex-Dividend Date	Dec 29, 2025

Volume	16,088
Open	2,290.00
Previous Close	2,295.00
Day's Range	2,120.00 - 2,290.00
52-Week Range	494.00 - 2,595.00
Beta	0.03
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About C&R Research

C&R Research Inc. engages in the of clinical development for pharmaceuticals and medical devices. The company’s therapeutic area comprises oncology, cardiovascular, endocrinology, dermatology, central nervous system, ophthalmology, and rare disease.The company was founded in 1997 and is based in Seoul, South Korea. [Read more]

Industry Commercial Physical and Biological Research

Founded 1997

Employees 486

Stock Exchange KOSDAQ

Ticker Symbol 359090

Full Company Profile

Financial Performance

In 2025, C&R Research's revenue was 64.98 billion, an increase of 8.87% compared to the previous year's 59.69 billion. Earnings were 2.59 billion, a decrease of -32.64%.

Financial Statements